MedTrace Logo

Optimal Treatment Strategy Based on for Pediatric AML

NCT02848183 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2016-07-28

No results posted yet for this study

Summary

The purpose of this study is to optimize therapy according to the known risk factors and treatment response in pediatric acute myeloid leukemia (AML)

Conditions

  • Pediatric Acute Myeloid Leukemia

Interventions

DRUG

Cytarabine

DRUG

Idarubicin

DRUG

Mitoxantrone

DRUG

Etoposide

PROCEDURE

Hematopoietic stem cell transplantation

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02848183 on ClinicalTrials.gov